RANKL inhibition for the management of patients with benign metabolic bone disorders. - Wikidata - wikimedia - TriplyDB

RANKL inhibition for the management of patients with benign metabolic bone disorders.

RANKL inhibition for the management of patients with benign metabolic bone disorders.

http://www.wikidata.org/entity/Q37532561

about

Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab Giant cell tumor in a case of Paget's disease of bone: an aggressive benign tumor exhibiting a quick response to an innovative therapeutic agent.The facial skeleton in patients with osteoporosis: a field for disease signs and treatment complications Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications.New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response.New cancer therapies and jaw necrosis.Assessment of bone metabolism and biomechanical properties of the femur, following treatment with anastrozole and letrozole in an experimental model of menopause.Inhibition of receptor activator of nuclear factor kappa-B ligand pathway for the management of aggressive osteosarcoma.

P2860

Q28727655-248F1725-AFEA-4162-98B0-DE62C82B5B00 Q34417248-520170DC-C42A-4A16-AC1E-B9DF13F7D24A Q34590994-D1F8B7D5-E9FB-43C6-928A-4F1EF65E6E70 Q37829690-A95BBFE3-ACE9-4F47-BFE7-FA97638875F9 Q37917774-BBB3F5E3-C838-45D0-8EAC-FDBC6A02CE83 Q38584982-629D0522-9DED-428A-89CE-4BCA33BA30BD Q41388200-6E64888F-BEB8-4655-A135-1D031749BCF2 Q42330816-57693AA1-E42A-42B9-97A8-D56A8454CA6E

P2860

RANKL inhibition for the management of patients with benign metabolic bone disorders.

http://www.wikidata.org/entity/Q37532561

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

RANKL inhibition for the management of patients with benign metabolic bone disorders.

@en

RANKL inhibition for the management of patients with benign metabolic bone disorders.

@nl

type

label

RANKL inhibition for the management of patients with benign metabolic bone disorders.

@en

RANKL inhibition for the management of patients with benign metabolic bone disorders.

@nl

prefLabel

RANKL inhibition for the management of patients with benign metabolic bone disorders.

@en

RANKL inhibition for the management of patients with benign metabolic bone disorders.

@nl

P1433

Q37532561-00D9F34E-AA70-4107-8728-ED8FFF73F6E9

P1476

Q37532561-7472334E-27BB-459C-AAC2-1DE592666C35

P2093

Q37532561-2648B82A-2F6D-4CE9-9756-0B101F67A168

Q37532561-5482F1DA-96E0-4490-A489-F82E99783835

Q37532561-C964CE5D-FC12-4F53-842E-85574A85F082

P2860

Q37532561-0246D07D-AF51-4DE8-9B25-3F27AC776F8E

Q37532561-030FC409-7951-4DE2-96AF-9CB1F3E980A2

Q37532561-036BBE15-7F44-4103-9B9C-12209EE0DA85

Q37532561-039F21BA-4E85-406A-BA2B-79BE84A2150C

Q37532561-03CA2EE7-5860-4EA2-AA7A-3E6BB4381D08

Q37532561-0536D307-719C-4B38-9257-C8A031D91599

Q37532561-084BFD59-BD8E-42BA-A63B-DA522BA9E0C6

Q37532561-0A0BA7F7-C22C-4D27-AD40-8351A584EB0C

Q37532561-0D83A814-A860-44B9-B7F5-EF1A801D97B9

Q37532561-0ED5B400-19A5-4DA2-BCF7-FA4512205320

P304

Q37532561-12558D17-B692-4987-9DBB-DA40E2E54D2C

P31

Q37532561-CBCF72E8-F64A-47D4-A80C-D24B5A6F4139

P356

Q37532561-5D250C05-68C3-4F91-8721-1F2516FE12DD

P407

Q37532561-D6793787-9422-4EC1-ADB9-3B9852645E83

P433

Q37532561-48C9F1CB-D9A6-4BA3-80EE-17CD99A78E8E

P478

Q37532561-5B4BFCF5-031B-4C18-A4C9-6722035678E8

P50

Q37532561-506919F3-E6AA-48D1-A183-51F3305A428D

P577

Q37532561-7EA2716E-A3F8-4EFA-88B8-2934E39375FC

P698

Q37532561-E90C7CA8-4D53-4AFB-8798-6439746706C9

P356

13543780903048929

P1433

Expert Opinion on Investigational Drugs

P1476

RANKL inhibition for the management of patients with benign metabolic bone disorders

@en

P2093

Athanasios D Anastasilakis

http://www.w3.org/2001/XMLSchema#string

Evangelos Terpos

http://www.w3.org/2001/XMLSchema#string

Konstantinos A Toulis

http://www.w3.org/2001/XMLSchema#string

P2860

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

Identification and characterization of a new member of the TNF family that induces apoptosis

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

RANK is essential for osteoclast and lymph node development

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis

Denosumab in postmenopausal women with low bone mineral density

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

Osteoclast differentiation and activation

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

P304

1085-1102

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543780903048929

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Stergios A. Polyzos

P577

2009-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19558335

http://www.w3.org/2001/XMLSchema#string